Literature DB >> 34274053

In-hospital complications associated with COVID-19.

Xiaoying Gu1, Bin Cao2.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 34274053      PMCID: PMC8285113          DOI: 10.1016/S0140-6736(21)00983-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
As the COVID-19 pandemic persists globally, an emerging challenge is the shift from acute infection to the burden of long-term consequences resulting from the disease. Although a consensus terminology has not yet been reached, the post-acute stage of COVID-19 is mostly defined as 3 or 4 weeks after symptom onset, and long or chronic COVID-19 is defined as symptoms and abnormalities persisting or presenting beyond 12 weeks.2, 3 Most studies have focused on acute and subacute COVID-19, although evidence-based guidance for the management of long COVID-19 is limited. Comprehensively understanding the health effects of COVID-19 from its acute to chronic stages is important, not only for the preparation of further waves of the pandemic, but also for assessing the burden on health-care systems due to COVID-19 consequences. In The Lancet, Thomas Drake and colleagues report their prospective study of in-hospital complications of COVID-19 and the impact on clinical prognosis at discharge, initiated at the early stages of the pandemic. 73 197 adult patients were studied, of whom 44% were female and 73% were White, from 302 UK health-care facilities, with COVID-19 and admitted to hospital between Jan 4 and Aug 4, 2020. The study showed that among those admitted to hospital with COVID-19, a high proportion (49·7%) had at least one complication. The occurrence of complications was not only associated with a higher risk of mortality during hospitalisation, but also reduced the ability of patients to self-care once discharged. In most COVID-19 studies, mortality and respiratory support during hospitalisation have been used as hard endpoints; however, in this study, the authors have shifted the attention and instead use multi-organ complications during hospitalisation as the main endpoint. Furthermore, despite the mean age of this cohort being 71·1 years (SD 18·7), they also focused on younger patients in whom the case fatality rate was low but might suffer more from post-acute COVID-19. Previous studies have mainly focused on patients with COVID-19 who are most susceptible to complications, such as older people (aged ≥50 years) and those with more comorbidities. Drake and colleagues' findings about risk factors of complications are consistent with previous results. Their results show that the increasing risk of complications affecting a specific organ is positively associated with pre-existing comorbidities of the same organ, age, and gender for nearly all types of complications, except for gastrointestinal and liver complications. Further assessment of the association of complications with survival status and critical care shows both numbers and types of complications matter, with more complications associated with worse survival status (log-rank p<0·001), and complex respiratory (hazard ratio 2·15, 95% CI 2·04–2·27) and cardiovascular (1·98, 1·85–2·11) complications showing the strongest association with survival status. Nevertheless, the relative effect of complications on survival status and quality of life among people of different age groups was not previously understood. One of the most notable findings in this study is that the relative risk of death is much higher in younger patients with complications when compared with those of the same age who did not suffer a complication, whereas in older patients, the relative impact of complications on mortality appears to be lower. Whether this difference in complications on mortality was statistically significant was not examined by the authors. This finding is independent of the presence and number of comorbidities and indicates that attention should also be paid to younger patients who are less likely to die during the acute phase but more likely to live longer with complications in the days after acute or subacute COVID-19. By dissecting the effect of multi-organ complications of COVID-19 from different angles including age, gender, and comorbidity, the study provides inspiring ideas for long-term cohort studies by balancing attention between younger and older patients. However, several questions need to be answered in future studies. First, this study only focused on in-hospital complications and its effect on survival status and ability of self-care at discharge. Therefore, the effect of complications on long-term consequences need to be assessed. Second, socioeconomics, race, and ethnicity are important considerations for long COVID-19. The authors described the proportions of complications among patients with different ethnicities and included deprivation as a confounding factor without further comprehensive evaluation. It would be interesting and informative to examine the data regarding socioeconomics and ethnicity as the authors have done for age, gender, and comorbidity. Finally, although the model construction was robust, residual confounding effects cannot be excluded. Some factors such as the sequential organ failure assessment score and D-dimer on admission, and the use of dexamethasone that were shown to be related to in-hospital mortality were not adjusted.6, 7 The public health effect of post-acute COVID-19 is substantial considering the large number of people infected by SARS-CoV-2 globally. In addition to delineating the diverse manifestation across the full clinical spectrum of post-acute COVID-19, the pathophysiological mechanisms attributable to post-acute COVID-19, especially long COVID-19, need to be further elucidated among people with different demographic and clinical characteristics. Furthermore, research on the effects of the serological features, together with immunological aberrations and inflammatory damage resulting from acute SARS-CoV-2 infection, on post-acute or long COVID-19 is needed.
  8 in total

1.  A Proposed Framework and Timeline of the Spectrum of Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health Implications.

Authors:  S Deblina Datta; Amish Talwar; James T Lee
Journal:  JAMA       Date:  2020-12-08       Impact factor: 56.272

2.  Long-term Health Consequences of COVID-19.

Authors:  Carlos Del Rio; Lauren F Collins; Preeti Malani
Journal:  JAMA       Date:  2020-11-03       Impact factor: 56.272

3.  Management of post-acute covid-19 in primary care.

Authors:  Trisha Greenhalgh; Matthew Knight; Christine A'Court; Maria Buxton; Laiba Husain
Journal:  BMJ       Date:  2020-08-11

Review 4.  Post-acute COVID-19 syndrome.

Authors:  Ani Nalbandian; Kartik Sehgal; Aakriti Gupta; Mahesh V Madhavan; Claire McGroder; Jacob S Stevens; Joshua R Cook; Anna S Nordvig; Daniel Shalev; Tejasav S Sehrawat; Neha Ahluwalia; Behnood Bikdeli; Donald Dietz; Caroline Der-Nigoghossian; Nadia Liyanage-Don; Gregg F Rosner; Elana J Bernstein; Sumit Mohan; Akinpelumi A Beckley; David S Seres; Toni K Choueiri; Nir Uriel; John C Ausiello; Domenico Accili; Daniel E Freedberg; Matthew Baldwin; Allan Schwartz; Daniel Brodie; Christine Kim Garcia; Mitchell S V Elkind; Jean M Connors; John P Bilezikian; Donald W Landry; Elaine Y Wan
Journal:  Nat Med       Date:  2021-03-22       Impact factor: 53.440

Review 5.  Toward Understanding COVID-19 Recovery: National Institutes of Health Workshop on Postacute COVID-19.

Authors:  Andrea M Lerner; Daphne A Robinson; Linda Yang; Carolyn F Williams; Lori M Newman; Joseph J Breen; Robert W Eisinger; Johanna S Schneider; Adaora A Adimora; Emily J Erbelding
Journal:  Ann Intern Med       Date:  2021-03-30       Impact factor: 25.391

6.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

7.  Dexamethasone in Hospitalized Patients with Covid-19.

Authors:  Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray
Journal:  N Engl J Med       Date:  2020-07-17       Impact factor: 91.245

8.  Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study.

Authors:  Thomas M Drake; Aya M Riad; Cameron J Fairfield; Conor Egan; Stephen R Knight; Riinu Pius; Hayley E Hardwick; Lisa Norman; Catherine A Shaw; Kenneth A McLean; A A Roger Thompson; Antonia Ho; Olivia V Swann; Michael Sullivan; Felipe Soares; Karl A Holden; Laura Merson; Daniel Plotkin; Louise Sigfrid; Thushan I de Silva; Michelle Girvan; Clare Jackson; Clark D Russell; Jake Dunning; Tom Solomon; Gail Carson; Piero Olliaro; Jonathan S Nguyen-Van-Tam; Lance Turtle; Annemarie B Docherty; Peter Jm Openshaw; J Kenneth Baillie; Ewen M Harrison; Malcolm G Semple
Journal:  Lancet       Date:  2021-07-17       Impact factor: 79.321

  8 in total
  1 in total

Review 1.  Recent review of COVID-19 management: diagnosis, treatment and vaccination.

Authors:  Vivek P Chavda; Suneetha Vuppu; Toshika Mishra; Sathvika Kamaraj; Aayushi B Patel; Nikita Sharma; Zhe-Sheng Chen
Journal:  Pharmacol Rep       Date:  2022-10-10       Impact factor: 3.919

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.